

In this issue

Review Article

[Open Access](#) [Review Article](#) PTZAID:SJGGT-4-116

## Caveolin-1 in renal disease

Published On: July 28, 2018 | Pages: 007 - 014

Author(s): Sourabh Chand\*

Caveolin-1 is the essential structural formation for lipid raft formation. It has been ascribed to several disease processes in humans due to its ubiquitous distribution. Patients with chronic kidney disease suffer great morbidity and mortality where manipulation of caveolin-1 could lead to new potential therapeutic targets in this patient group. This review highlight ...

[Abstract View](#) [Full Article View](#) [DOI: 10.17352/sjggt.000016](#)

Mini Review

[Open Access](#) [Mini Review](#) PTZAID:SJGGT-4-115

## Strategies for investigating the genetics of chronic kidney disease

Published On: July 28, 2018 | Pages: 004 - 006

Author(s): Sourabh Chand\*

This short review describes the strategies employed for investigating genetic variation in chronic kidney disease as well as highlighting potential shortfalls that should be overcome in future studies. ...

[Abstract View](#) [Full Article View](#) [DOI: 10.17352/sjggt.000015](#)

[Open Access](#) [Mini Review](#) PTZAID:SJGGT-4-114

## Lenalidomide as potential treatment in small cell neuroendocrine lung cancer with del 5q

Published On: July 11, 2018 | Pages: 002 - 003

Author(s): Paul Hartel\*

Lung cancer is a leading cause of cancer deaths world-wide, with the carcinogens in tobacco smoke playing a major etiologic role. Genetic changes responsible for carcinogenesis include activation of proto-oncogenes and inactivation of tumor suppressor genes. Tumor suppressor gene inactivation is contributed to, in part, by loss of chromosomal DNA.

While cytogenetic fi ...

[Abstract View](#) | [Full Article View](#) | DOI: 10.17352/siggt.000014

## Opinion

[Open Access](#) [Opinion](#) PTZAID:SJGGT-4-113

### First Treatment for Breast Cancer with certain Inherited Gene Mutation

Published On: February 15, 2018 | Pages: 001 - 001

Author(s): Sulaiman Naseer\*

The U.S. Food and Drug Administration approved use of Lynparza (olaparib tablets) treat certain types of breast cancer that have spread (metastasized) and whose tumors have a specific inherited (germline) genetic mutation, making it the first drug in its class (PARP inhibitor) approved to treat breast cancer. ...

[Abstract View](#) | [Full Article View](#) | DOI: 10.17352/siggt.000013